Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces its appointment as Financial PR advisor to AIM listed healthcare company Advanced Oncotherapy plc (AIM: AVO). Walbrook is ranked No.1 for Healthcare in the AIM Advisers Rankings Guide.
AVO is a provider of internationally endorsed technology for advanced radiotherapy systems that are available to treat common and rare cancers. Around the world today, more than 60% of cancer patients receive radiotherapy treatment as part of their cancer care. Radiation is damaging as radiotherapy harms healthy tissue and can cause short and long-term complications that are well documented in the literature.
AVO seeks to develop the technology and techniques to maximise the destructive effect of radiotherapy on the tumour while keeping healthy tissue healthy. They are a leader in affordable and accessible proton beam therapy along with other technologies such SD-IORT. AVO's focus is to develop advanced, cost effective and patient-friendly radiotherapy treatments which are clinically superior to those currently available.
Paul McManus, Director of Walbrook PR, said: "We are delighted to have been appointed by Advanced Oncotherapy as a client at such an exciting period of change within the company. They represent the next generation of radiation treatment using Linac Image Guided Hadron Technology (LIGHT) therapy and with this, significantly reduce the side effects of invasive cancer treatments. Walbrook has built up a very strong position in the Life Sciences space, which combines well with our passion for working growing businesses, securing our position as the No. 1 Financial PR agency for AIM listed healthcare stocks."